ÂÜÀòÂÒÂ×

Mr. Hancock was appointed to the Board of Directors in November 2017 and served as interim President and Chief Executive Officer from May 2019 to July 2020. Mr. Hancock has worked in the biologic CDMO industry for over 30 years in various operational and executive roles, serving most recently as President and Chief Executive Officer of Althea Technologies, Inc., a large molecule CDMO producing a wide range of biologics, vaccines and parenteral products. In addition to Althea, Mr. Hancock has held senior management positions at The Immune Response Corporation, and Hybritech Inc. (now part of Eli Lilly & Company), and is currently the Chairman of the Board and Executive Director of Argonaut Manufacturing Services, Inc., a privately-owned CDMO focused on the biotechnology and life sciences industries. He also serves on the Board of Directors of Tempo Therapeutics, a privately-held company, focused on cell therapy and vaccine technology including BioCina, a CDMO, focused on the development and cGMP manufacture of microbial-based therapeutics. Mr. Hancock received a B.A. in Microbiology from Miami University.